SINUS-24 and SINUS-52

In SINUS-52, 51% total improvement in NC score with DUPIXENT 300 mg Q2W + INCS was seen at Week 24 (n=295, pooled DUPIXENT arms) (-1.25 from a baseline score of 2.46) vs 15% improvement with placebo + INCS (n=153) (-0.38 from a baseline score of 2.38) (LSM difference vs placebo: -0.87 [95% CI: -1.03, -0.71]) (coprimary endpoint) (P<0.0001).1,4

Week 24 in SINUS-24 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=143) and placebo + INCS (n=133): -0.89 (95% CI: -1.07, -0.71) (-1.34 from a baseline score of 2.26 vs -0.45 from a baseline score of 2.45, respectively) (P<0.0001).1,4

Rapid relief in nasal congestion was seen as early as Day 2.6,a (Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.)6

aLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).6,8

Nasal congestion/obstruction (NC) score (range 0 to 3): reduced score indicates improvement.1

NCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

See the full data on nasal congestion and obstruction